<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30334464</PMID>        <DateRevised>            <Year>2018</Year>            <Month>10</Month>            <Day>18</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1651-226X</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Oct</Month>                        <Day>18</Day>                    </PubDate>                </JournalIssue>                <Title>Acta oncologica (Stockholm, Sweden)</Title>                <ISOAbbreviation>Acta Oncol</ISOAbbreviation>            </Journal>            <ArticleTitle>Cancer-related distress in unselected women with newly diagnosed breast or ovarian cancer undergoing BRCA1/2 testing without pretest genetic counseling.</ArticleTitle>            <Pagination>                <MedlinePgn>1-7</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1080/0284186X.2018.1502466</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Genetic testing is increasing in patients newly diagnosed with cancer. This study investigated the levels, course and predictors of cancer-related distress, defined as intrusion and avoidance, in women undergoing BRCA1/2 testing without pretest genetic counseling shortly after a diagnosis of breast or ovarian cancer.</AbstractText>                <AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">Unselected for family history or age, 259 women with breast cancer and 50 women with ovarian cancer, underwent BRCA1/2 testing shortly after diagnosis. Cancer-related distress was measured with the Impact of Event Scale before and after genetic testing. In order to identify predictors of distress, the subscale scores were regressed on baseline predictor variables including sociodemographic and medical variables, perceived social support, and decisional conflict regarding genetic testing.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The mean levels of intrusion and avoidance were in the moderate range both before and after genetic testing with a statistically significant decline during follow-up. Younger age, shorter time since diagnosis, lower levels of social support, and a diagnosis of ovarian cancer predicted higher levels of both intrusion and avoidance. In addition, higher levels of decisional conflict and living with a partner predicted higher levels of intrusion.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Women having genetic testing shortly after a diagnosis of breast or ovarian cancer had a moderate mean level of cancer-related distress, which decreased with time. Health personnel offering genetic testing to newly diagnosed women with breast or ovarian cancer should be aware of the potential predictors for increased cancer-related distress identified in this study: younger age, less perceived social support, higher levels of decisional conflict regarding genetic testing, and living with a partner.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Høberg-Vetti</LastName>                    <ForeName>Hildegunn</ForeName>                    <Initials>H</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-9876-576X</Identifier>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b Department of Clinical Science , University of Bergen , Bergen, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Eide</LastName>                    <ForeName>Geir Egil</ForeName>                    <Initials>GE</Initials>                    <AffiliationInfo>                        <Affiliation>c Centre for Clinical Research , Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>d Department of Global Public Health and Primary Care , University of Bergen , Bergen, Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Siglen</LastName>                    <ForeName>Elen</ForeName>                    <Initials>E</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-3486-1071</Identifier>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Listøl</LastName>                    <ForeName>Wenche</ForeName>                    <Initials>W</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0002-2001-0850</Identifier>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Haavind</LastName>                    <ForeName>Marianne Tveit</ForeName>                    <Initials>MT</Initials>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hoogerbrugge</LastName>                    <ForeName>Nicoline</ForeName>                    <Initials>N</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2393-8141</Identifier>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>e Department of Human Genetics , Radboud University Medical Center , Nijmegen , The Netherlands.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Bjorvatn</LastName>                    <ForeName>Cathrine</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>a Western Norway Familial Cancer Center , Department of Medical Genetics, Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>b Department of Clinical Science , University of Bergen , Bergen, Norway.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>f Department of Research and Development , Haukeland University Hospital , Bergen , Norway.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Acta Oncol</MedlineTA>            <NlmUniqueID>8709065</NlmUniqueID>            <ISSNLinking>0284-186X</ISSNLinking>        </MedlineJournalInfo>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>10</Month>                <Day>19</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>10</Month>                <Day>20</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30334464</ArticleId>            <ArticleId IdType="doi">10.1080/0284186X.2018.1502466</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>